Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2018, Article ID 8567912, 8 pages
https://doi.org/10.1155/2018/8567912
Review Article

Current Evidence for the Prevention of Endophthalmitis in Anti-VEGF Intravitreal Injections

1College of Medicine and Dentistry, James Cook University, Townsville, Australia
2Greenslopes Clinical School, Faculty of Medicine, University of Queensland, Brisbane, Australia

Correspondence should be addressed to C. J. Layton; ua.ude.qu@notyal.c

Received 3 April 2018; Accepted 31 May 2018; Published 24 July 2018

Academic Editor: Manuel S. Falcão

Copyright © 2018 P. ET. Lau et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Lanzetta, P. Mitchell, S. Wolf, and D. Veritti, “Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review,” British Journal of Ophthalmology, vol. 97, no. 12, pp. 1497–1507, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. M. M. Sachdeva, A. Moshiri, H. A. Leder, and A. W. Scott, “Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms,” Journal of Ophthalmic Inflammation and Infection, vol. 6, no. 2, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. J. O. Mason III, M. F. White, R. M. Feist et al., “Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection,” Retina, vol. 28, no. 4, pp. 564–567, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. A. R. Bhavsar, J. M. Googe Jr., C. R. Stockdale et al., “Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials,” Archives of Ophthalmology, vol. 127, no. 12, pp. 1581–1583, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Merani and A. P. Hunyor, “Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review,” International Journal of Retina and Vitreous, vol. 1, no. 1, 2015. View at Publisher · View at Google Scholar
  6. A. Grzybowski, P. Kanclerz, and W. G. Myers, “The use of povidone-iodine in ophthalmology,” Current Opinion in Ophthalmology, vol. 29, no. 1, pp. 19–32, 2018. View at Publisher · View at Google Scholar · View at Scopus
  7. A. R. Bhavsar, A. R. Glassman, C. R. Stockdale, and L. M. Jampol, “Elimination of Topical Antibiotics for Intravitreous Injections and the Importance of Using Povidone-Iodine: Update From the Diabetic Retinopathy Clinical Research Network,” JAMA Ophthalmology, vol. 134, no. 10, pp. 1181–1183, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Safar and M. C. Dellimore, “The effect of povidone-iodine flush versus drops on conjunctival colonization before intravitreal injections,” International Ophthalmology, vol. 27, no. 5, pp. 307–312, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. D. A. Friedman, J. O. Mason III, T. Emond, and G. McGwin Jr., “Povidone-iodine contact time and lid speculum use during intravitreal injection,” Retina, vol. 33, no. 5, pp. 975–981, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Saedon, J. Nosek, J. Phillips, N. Narendran, and Y. C. Yang, “Ocular surface effects of repeated application of povidone-iodine in patients receiving frequent intravitreal injections,” Cutaneous and Ocular Toxicology, vol. 36, no. 4, pp. 343–346, 2017. View at Publisher · View at Google Scholar · View at Scopus
  11. C. L. Oakley and B. J. Vote, “Aqueous chlorhexidine (0.1%) is an effective alternative to povidone-iodine for intravitreal injection prophylaxis,” Acta Ophthalmologica, vol. 94, no. 8, pp. e808–e809, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Oakley, P. Allen, J. Hooshmand, and B. J. T. Vote, “Pain and antisepsis after ocular administration of povidone-iodine versus chlorhexidine,” Retina, 2017, In press. View at Publisher · View at Google Scholar
  13. R. Merani, Z. E. McPherson, A. P. Luckie et al., “Aqueous chlorhexidine for intravitreal injection antisepsis: a case series and review of the literature,” Ophthalmology, vol. 123, no. 12, pp. 2588–2594, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Grzybowski and P. Brona, “Povidone-iodine is still a premium antiseptic measure in ocular surgery,” Acta Ophthalmologica, vol. 95, no. 3, pp. e253–e254, 2017. View at Publisher · View at Google Scholar · View at Scopus
  15. D. A. Boes, T. D. Lindquist, T. R. Fritsche, and R. E. Kalina, “Effects of povidone-iodine chemical preparation and saline irrigation on the perilimbal flora,” Ophthalmology, vol. 99, no. 10, pp. 1569–1574, 1992. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Samia-Aly, A. Cassels-Brown, D. S. Morris, R. Stancliffe, and J. E. Somner, “A survey of UK practice patterns in the delivery of intravitreal injections,” Ophthalmic and Physiological Optics, vol. 35, no. 4, pp. 450–454, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Xing, S. J. Dorrepaal, and J. Gale, “Survey of intravitreal injection techniques and treatment protocols among retina specialists in Canada,” Canadian Journal of Ophthalmology, vol. 49, no. 3, pp. 261–266, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. F. J. Freiberg, T. Brynskov, M. R. Munk et al., “Low endophthalmitis rates after intravitreal anti-vascular endothelial growth factor injections in an operation room: a retrospective multicenter study,” Retina, vol. 37, no. 12, pp. 2341–2346, 2017. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Tabandeh, F. Boscia, A. Sborgia et al., “Endophthalmitis associated with intravitreal injections: office-based setting and operating room setting,” Retina, vol. 34, no. 1, pp. 18–23, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. M. F. Bande, R. Mansilla, M. P. Pata et al., “Intravitreal injections of anti-VEGF agents and antibiotic prophylaxis for endophthalmitis: a systematic review and meta-analysis,” Scientific Reports, vol. 7, no. 1, p. 18088, 2017. View at Publisher · View at Google Scholar · View at Scopus
  21. R. G. Abell, N. M. Kerr, P. Allen, and B. J. Vote, “Intravitreal injections: is there benefit for a theatre setting?” British Journal of Ophthalmology, vol. 96, no. 12, pp. 1474–1478, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Dharan and D. Pittet, “Environmental controls in operating theatres,” Journal of Hospital Infection, vol. 51, no. 12, pp. 79–84, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Lapid-Gortzak, R. Traversari, J. W. van der Linden, S. Y. Lesnik Oberstein, O. Lapid, and R. O. Schlingemann, “Mobile ultra-clean unidirectional airflow screen reduces air contamination in a simulated setting for intra-vitreal injection,” International Ophthalmology, vol. 37, no. 1, pp. 131–137, 2017. View at Publisher · View at Google Scholar · View at Scopus
  24. Endophthalmitis Study Group and European Society of Cataract & Refractive Surgeons, “Prophylaxis of postoperative endophthalmitis following cataract surgery, results of the ESCRS multicenter study and identification of risk factors,” Journal of Cataract & Refractive Surgery, vol. 33, no. 6, pp. 978–988, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Q. Yu and C. N. Ta, “Prevention and treatment of injection-related endophthalmitis,” Graefe’s Archive for Clinical and Experimental Ophthalmology, vol. 252, no. 7, pp. 1027–1031, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Chen, M. Y. Lin, J. Cox, and D. M. Brown, “Endophthalmitis after intravitreal injection: the importance of viridans streptococci,” Retina, vol. 31, no. 8, pp. 1525–1533, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. C. A. McCannel, “Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies,” Retina, vol. 31, no. 4, pp. 654–661, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. S. J. Garg, M. Dollin, J. Hsu, P. Storey, and J. F. Vander, “Effect of a strict ‘No-Talking’ policy during intravitreal injection on post-injection endophthalmitis,” Ophthalmic Surgery, Lasers & Imaging Retina, vol. 46, no. 10, pp. 1028–1034, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. R. R. Doshi, T. Leng, and A. E. Fung, “Reducing oral flora contamination of intravitreal injections with face mask or silence,” Retina, vol. 32, pp. 473–476, 2012. View at Google Scholar
  30. K. Huang, M. B. Sultan, D. Zhou, C. S. Tressler, and J. Mo, “Practice patterns of ophthalmologists administering intravitreal injections in Europe: a longitudinal survey,” Clinical Ophthalmology, vol. 10, pp. 2485–2488, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. A. E. Green-Simms, N. S. Ekdawi, and S. J. Bakri, “Survey of intravitreal injection techniques among retinal specialists in the United States,” American Journal of Ophthalmology, vol. 151, no. 2, pp. 329–332, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. O. Segal, Y. Segal-Trivitz, A. Y. Nemet, N. Geffen, R. Nesher, and M. Mimouni, “Survey of intravitreal injection techniques among retina specialists in Israel,” Clinical Ophthalmology, vol. 10, pp. 1111–1116, 2016. View at Google Scholar
  33. C. S. Cheung, A. W. Wong, A. Lui, P. J. Kertes, R. G. Devenyi, and W. C. Lam, “Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections,” Ophthalmology, vol. 119, no. 8, pp. 1609–1614, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Tanner, J. C. Dumville, G. Norman, and M. Fortnam, “Surgical hand antisepsis to reduce surgical site infection,” Cochrane Database of Systematic Reviews, Article ID Cd004288, 2016. View at Publisher · View at Google Scholar · View at Scopus
  35. M. G. Tuuli, J. Liu, M. J. Stout et al., “A randomized trial comparing skin antiseptic agents at cesarean delivery,” New England Journal of Medicine, vol. 374, no. 7, pp. 647–655, 2016. View at Publisher · View at Google Scholar · View at Scopus
  36. N. J. Shen, S. C. Pan, W. H. Sheng et al., “Comparative antimicrobial efficacy of alcohol-based hand rub and conventional surgical scrub in a medical center,” Journal of Microbiology, Immunology and Infection, vol. 48, no. 3, pp. 322–328, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. K. W. Lai, T. L. Foo, W. Low, and G. Naidu, “Surgical hand antisepsis-a pilot study comparing povidone-iodine hand scrub and alcohol-based chlorhexidine gluconate hand rub,” Annals of the Academy of Medicine, Singapore, vol. 41, pp. 12–16, 2012. View at Google Scholar
  38. M. L. Rotter, G. Kampf, M. Suchomel, and M. Kundi, “Population kinetics of the skin flora on gloved hands following surgical hand disinfection with 3 propanol-based hand rubs: a prospective, randomized, double-blind trial,” Infection Control & Hospital Epidemiology, vol. 28, no. 3, pp. 346–350, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. M. S. Fineman, J. Hsu, M. J. Spirn, and R. S. Kaiser, “Bimanual assisted eyelid retraction technique for intravitreal injections,” Retina, vol. 33, no. 9, pp. 1968–1970, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. E. S. Gragoudas, A. P. Adamis, E. T. Cunningham Jr., M. Feinsod, and D. R. Guyer, “Pegaptanib for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 351, no. 27, pp. 2805–2816, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Munro, G. R. Williams, A. Ells et al., “Lid splinting eyelid retraction technique: a minimised sterile approach for intravitreal injections,” British Journal of Ophthalmology, 2017. View at Publisher · View at Google Scholar
  42. E. Rahimy, M. S. Fineman, C. D. Regillo et al., “Speculum versus bimanual lid retraction during intravitreal injection,” Ophthalmology, vol. 122, no. 8, pp. 1729-1730, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Storey, M. Dollin, J. Pitcher et al., “The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection,” Ophthalmology, vol. 121, no. 1, pp. 283–289, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Reibaldi, A. Pulvirenti, T. Avitabile et al., “Pooled estimates of incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents with and without topical antibiotic prophylaxis,” Retina, vol. 38, no. 1, pp. 1–11, 2018. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Hsu, A. T. Gerstenblith, S. J. Garg, and J. F. Vander, “Conjunctival flora antibiotic resistance patterns after serial intravitreal injections without postinjection topical antibiotics,” American Journal of Ophthalmology, vol. 157, no. 3, pp. 514–518.e1, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. E. Milder, J. Vander, C. Shah, and S. Garg, “Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection,” Ophthalmology, vol. 119, no. 7, pp. 1420–1424, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Gambrell and S. Schaal, “Topical anesthesia for intravitreal injection,” Expert Opinion on Drug Delivery, vol. 9, no. 7, pp. 731–733, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. H. F. Shiroma, A. K. K. Takaschima, M. E. Farah et al., “Patient pain during intravitreal injections under topical anesthesia: a systematic review,” International Journal of Retina and Vitreous, vol. 3, no. 1, p. 23, 2017. View at Publisher · View at Google Scholar
  49. S. M. Cohen, K. Billiris-Findlay, D. A. Eichenbaum, and S. E. Pautler, “Topical lidocaine gel with and without subconjunctival lidocaine injection for intravitreal injection: a within-patient study,” Ophthalmic Surgery, Lasers & Imaging Retina, vol. 45, pp. 306–310, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. G. C. Andrade and A. C. Carvalho, “Comparison of 3 different anesthetic approaches for intravitreal injections: a prospective randomized trial,” Arquivos Brasileiros de Oftalmologia, vol. 78, pp. 27–31, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Tustin, S. J. Kim, A. Chomsky, G. B. Hubbard III, and J. Sheng, “Antibacterial properties of 2% lidocaine and reduced rate of endophthalmitis after intravitreal injection,” Retina, vol. 34, no. 5, pp. 935–942, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. Z. D. Inman and N. G. Anderson, “Incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using topical lidocaine gel anesthesia,” Retina, vol. 31, no. 4, pp. 669–672, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. E. M. Lad, M. G. Maltenfort, and T. Leng, “Effect of lidocaine gel anesthesia on endophthalmitis rates following intravitreal injection,” Ophthalmic Surgery, Lasers, and Imaging, vol. 43, no. 2, pp. 115–120, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. D. L. Chao, N. Z. Gregori, J. Khandji, and R. Goldhardt, “Safety of bilateral intravitreal injections delivered in a teaching institution,” Expert Opinion on Drug Delivery, vol. 11, no. 7, pp. 991–993, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Ruao, M. Andreu-Fenoll, R. Dolz-Marco, and R. Gallego-Pinazo, “Safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents,” Clinical Ophthalmology, vol. 11, pp. 299–302, 2017. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Tabatabaii, A. Ahmadraji, A. Khodabande, and M. Mansouri, “Acute bilateral endophthalmitis following bilateral intravitreal bevacizumab (avastin) injection,” Middle East African Journal of Ophthalmology, vol. 20, no. 1, pp. 87-88, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. A. M. Derham, E. Chen, V. Y. Bunya, and R. E. O’Malley, “Bilateral herpetic keratitis after bilateral intravitreal bevacizumab for exudative macular degeneration,” Cornea, vol. 36, no. 7, pp. 878-879, 2017. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Giocanti-Auregan, R. Tadayoni, T. Grenet et al., “Estimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice,” BMC Ophthalmology, vol. 16, no. 1, p. 142, 2016. View at Publisher · View at Google Scholar · View at Scopus